PE20190339A1 - 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1 - Google Patents

1h-pirazolo[4,3-b] piridinas como inhibidores de pde1

Info

Publication number
PE20190339A1
PE20190339A1 PE2018003262A PE2018003262A PE20190339A1 PE 20190339 A1 PE20190339 A1 PE 20190339A1 PE 2018003262 A PE2018003262 A PE 2018003262A PE 2018003262 A PE2018003262 A PE 2018003262A PE 20190339 A1 PE20190339 A1 PE 20190339A1
Authority
PE
Peru
Prior art keywords
methyl
group
pyridines
inhibitors
pde1
Prior art date
Application number
PE2018003262A
Other languages
English (en)
Inventor
Jan Kehler
Karsten Juhl
Mauro Marigo
Paulo Jorge Vieira Vital
Mikkel Jessing
Morten Langgård
Lars Kyhn Rasmussen
Carl Martin Sebastian Clementson
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of PE20190339A1 publication Critical patent/PE20190339A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Referido a un compuesto de formula (I), donde L se selecciona entre el grupo que consiste en NH, CH2, S y O; R1 se selecciona entre el grupo que consiste en H, alquilo C1-C5 lineal o ramificado, fluoroalquilo C1-C5, entre otros; R2 se selecciona entre el grupo que consiste en alquilo C1-C8 lineal o ramificado, cicloalquilo C3-C8 monociclico saturado, entre otros; R3 es metilo sustituido con fenilo, piridonilo, pirimidinilo, entre otros; R4 es CH2 y R3 es NH que esta sustituido con fenilo, piridonilo, entre otros; y sales farmaceuticamente aceptables de los mismos. Estos compuestos, 1H-pirazolo[4,3-b] piridinas, son inhibidores de la enzima PDE1, y un compuesto seleccionado es: 5-(2-etoxi-3-piridil)-1-isopropil-3-metil-N-[(5-metil-1,3,4-oxadiazol-2-il)metil]pirazolo[4,3-b]piridin-7-amina. Tambien se refiere a metodos para preparar estos compuestos y su uso en el tratamiento de trastornos neurodegenerativos y trastornos psiquiatricos.
PE2018003262A 2016-07-04 2017-06-30 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1 PE20190339A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201600397 2016-07-04
DKPA201600612 2016-10-11
DKPA201700236 2017-04-04

Publications (1)

Publication Number Publication Date
PE20190339A1 true PE20190339A1 (es) 2019-03-07

Family

ID=60806291

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018003262A PE20190339A1 (es) 2016-07-04 2017-06-30 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1

Country Status (38)

Country Link
US (7) US10034861B2 (es)
EP (2) EP3478681B1 (es)
JP (1) JP7096171B2 (es)
KR (2) KR102488909B1 (es)
CN (1) CN109311872B (es)
AU (1) AU2017291794C1 (es)
CA (1) CA3026857A1 (es)
CL (1) CL2019000010A1 (es)
CO (1) CO2018013803A2 (es)
CR (1) CR20190003A (es)
CY (1) CY1122957T1 (es)
DK (1) DK3478681T3 (es)
DO (1) DOP2018000266A (es)
EC (1) ECSP18093944A (es)
ES (1) ES2784655T3 (es)
GE (1) GEP20207172B (es)
HR (1) HRP20200440T1 (es)
HU (1) HUE048576T2 (es)
IL (1) IL263511B (es)
JO (1) JO3819B1 (es)
LT (1) LT3478681T (es)
MA (1) MA52593A (es)
ME (1) ME03672B (es)
MX (1) MX2018015734A (es)
MY (1) MY197140A (es)
PE (1) PE20190339A1 (es)
PH (1) PH12018502604A1 (es)
PL (1) PL3478681T3 (es)
PT (1) PT3478681T (es)
RS (1) RS60072B1 (es)
RU (1) RU2759380C2 (es)
SG (1) SG11201810965YA (es)
SI (1) SI3478681T1 (es)
SV (1) SV2018005801A (es)
TW (1) TWI763683B (es)
UA (1) UA122824C2 (es)
WO (1) WO2018007249A1 (es)
ZA (1) ZA201808257B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10034861B2 (en) * 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
US11634416B2 (en) * 2017-12-14 2023-04-25 H. Lundbeck A/S Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines
AR113926A1 (es) * 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
US10766893B2 (en) * 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
TW201927784A (zh) * 2017-12-20 2019-07-16 丹麥商Ｈ 朗德貝克公司 作為pde1抑制劑之大環
CN111511742B (zh) * 2017-12-20 2023-10-27 H.隆德贝克有限公司 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶
WO2020252229A2 (en) * 2019-06-14 2020-12-17 Disarm Therapeutics, Inc. Inhibitors of sarm1
CN112390750B (zh) * 2020-11-11 2022-03-01 常州大学 作为选择性磷酸二酯酶2抑制剂的喹啉酮类化合物及其制备方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
DE19942474A1 (de) * 1999-09-06 2001-03-15 Merck Patent Gmbh Pyrazolo[4,3-d]pyrimidine
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
RU2348633C2 (ru) * 2002-12-23 2009-03-10 Глаксо Груп Лимитед ПИРАЗОЛО[3,4-b]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗ
EP1763528B1 (en) 2004-07-05 2008-11-26 Astellas Pharma Inc. Pyrazolopyridine derivatives
KR100710430B1 (ko) * 2004-08-24 2007-04-24 삼성코닝 주식회사 면광원 장치 및 이를 갖는 백 라이트 유닛
DE602005014375D1 (de) 2004-10-19 2009-06-18 Neurocrine Biosciences Inc Crf-rezeptor-antagonisten und zugehörige verfahren
WO2006084251A2 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
RU2402549C3 (ru) 2005-04-14 2022-03-10 Оцука Фармасьютикал Ко., Лтд. Пиперазин-замещенные бензотиофены для лечения психических расстройств
AU2006329040C1 (en) 2005-12-22 2011-12-08 Newron Pharmaceuticals S.P.A. 2 -Phenylethylamino derivatives as calcium and/or sodium channel modulators
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
JP5837278B2 (ja) 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
MX2009009793A (es) 2007-03-14 2009-10-16 Ranbaxy Lab Ltd Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa.
EA201170773A1 (ru) 2008-12-06 2012-01-30 Интра-Селлулар Терапиз, Инк. Органические соединения
CA3120504A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
CN103068848B (zh) 2010-08-12 2015-11-25 伊莱利利公司 抗N3pGlu淀粉样蛋白BETA肽抗体及其用途
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
WO2012143143A1 (en) 2011-04-21 2012-10-26 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
CN104024258B (zh) * 2011-09-01 2017-02-15 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
CN104379578B (zh) 2012-03-19 2017-06-09 阿比德治疗公司 氨基甲酸酯化合物及其制备和使用方法
TW201533043A (zh) 2013-04-18 2015-09-01 Lundbeck & Co As H 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物
HUE049469T2 (hu) * 2013-06-21 2020-09-28 Zenith Epigenetics Ltd Új biciklusos bromodomén inhibitorok
UA116023C2 (uk) 2013-07-08 2018-01-25 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як антагоністи метаботропного глутаматного рецептора
WO2015026683A1 (en) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
UA117695C2 (uk) 2014-02-19 2018-09-10 Х. Луннбек А/С 2-аміно-3,5,5-трифтор-3,4,5,6-тетрагідропіридини як інгібітори bace1 для лікування хвороби альцгеймера
TWI599358B (zh) 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
WO2016042775A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic derivative
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
US20180044343A1 (en) 2015-03-16 2018-02-15 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic imidazolo derivative
US20160311831A1 (en) 2015-04-22 2016-10-27 H. Lundbeck A/S Imidazotriazinones as PDE1 Inhibitors
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
WO2017024004A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
EP3334720A1 (en) 2015-08-12 2018-06-20 H. Lundbeck A/S 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors
WO2017100276A1 (en) 2015-12-08 2017-06-15 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers
US10390177B2 (en) 2015-12-09 2019-08-20 Ford Global Technologies, Llc Alert for left-behind mobile device
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
US11634416B2 (en) 2017-12-14 2023-04-25 H. Lundbeck A/S Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines
TW201927784A (zh) 2017-12-20 2019-07-16 丹麥商Ｈ 朗德貝克公司 作為pde1抑制劑之大環
US10766893B2 (en) 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
CN111511742B (zh) 2017-12-20 2023-10-27 H.隆德贝克有限公司 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶

Also Published As

Publication number Publication date
US11491140B2 (en) 2022-11-08
MA52593A (fr) 2021-03-17
US20210015794A1 (en) 2021-01-21
US20180000786A1 (en) 2018-01-04
KR20190025606A (ko) 2019-03-11
EP3689874A1 (en) 2020-08-05
HUE048576T2 (hu) 2020-08-28
DOP2018000266A (es) 2019-03-15
US10806718B2 (en) 2020-10-20
CN109311872A (zh) 2019-02-05
CO2018013803A2 (es) 2019-01-18
PH12018502604A1 (en) 2019-10-21
SI3478681T1 (sl) 2020-04-30
RU2759380C2 (ru) 2021-11-12
UA122824C2 (uk) 2021-01-06
WO2018007249A1 (en) 2018-01-11
SG11201810965YA (en) 2019-01-30
US20200129480A1 (en) 2020-04-30
US11026923B2 (en) 2021-06-08
ME03672B (me) 2020-10-20
JP2019524689A (ja) 2019-09-05
RS60072B1 (sr) 2020-05-29
DK3478681T3 (da) 2020-03-23
EP3478681A1 (en) 2019-05-08
ECSP18093944A (es) 2019-01-31
TWI763683B (zh) 2022-05-11
US20200360343A1 (en) 2020-11-19
RU2018143324A3 (es) 2020-08-12
AU2017291794C1 (en) 2022-01-13
CY1122957T1 (el) 2021-10-29
TW201806950A (zh) 2018-03-01
CN109311872B (zh) 2021-08-20
US10034861B2 (en) 2018-07-31
CA3026857A1 (en) 2018-01-11
LT3478681T (lt) 2020-04-10
US20210023056A1 (en) 2021-01-28
CL2019000010A1 (es) 2019-02-22
US10512632B2 (en) 2019-12-24
HRP20200440T1 (hr) 2020-06-12
AU2017291794B2 (en) 2021-07-22
IL263511A (en) 2019-01-31
GEP20207172B (en) 2020-10-26
PL3478681T3 (pl) 2020-06-15
RU2018143324A (ru) 2020-08-04
ES2784655T3 (es) 2020-09-29
US20190105302A1 (en) 2019-04-11
KR20220154262A (ko) 2022-11-21
CR20190003A (es) 2019-05-06
KR102488909B1 (ko) 2023-01-13
AU2017291794A1 (en) 2018-12-20
US20200375950A1 (en) 2020-12-03
ZA201808257B (en) 2020-05-27
KR102576888B1 (ko) 2023-09-08
JO3819B1 (ar) 2021-01-31
US11026924B2 (en) 2021-06-08
JP7096171B2 (ja) 2022-07-05
JOP20180116A1 (ar) 2019-01-30
SV2018005801A (es) 2019-02-13
PT3478681T (pt) 2020-04-03
MY197140A (en) 2023-05-26
MX2018015734A (es) 2019-03-21
IL263511B (en) 2020-11-30
EP3478681B1 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
PE20190339A1 (es) 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
PE20161443A1 (es) Compuestos
AR091285A1 (es) Inhibidores de bromodominio y sus usos
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
PE20181198A1 (es) Derivados de heterociclos biciclicos condensados como agentes de control de plagas
UY37310A (es) Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo
AR106806A1 (es) Inhibidores triazol de acc y usos de los mismos
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
ES2721268T3 (es) Compuestos de pirazolo[1,5-a]pirimidina-5,7-diamina como inhibidores de CDK y su uso terapéutico
AR097431A1 (es) Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
PE20161368A1 (es) Inhibidores de diacilglicerol aciltranferasa 2
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
CO2018002829A2 (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm)
PE20160026A1 (es) Compuestos heterociclicos como agentes para control de plagas
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
PE20181853A1 (es) 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4h-pirazolo[4,3-c]piridin-4-onas como inhibidores de pde1
AR053120A1 (es) Aminopiridinas como inhibidores de beta secretasa
AR097543A1 (es) COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR097545A1 (es) COMPUESTOS A BASE DE PIRAZOLO[1,5-a]PIRIMIDINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
AR098171A1 (es) Piridinilimidazolonas como herbicidas
CO2018003367A2 (es) Benzamidas sustituidas con isoxazolina y análogos como insecticidas